Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses physician-patient dynamics in managing hair loss and highlights the emotional impacts, emphasizing the need for effective communication and patient education, but it reports no new clinical findings.

This review discusses the nocebo effect in dermatology, highlighting its mechanisms, implications, and strategies to manage it, but does not provide new clinical research findings.

Negative expectations can cause adverse effects in patients even without active treatment, and managing this nocebo effect involves better communication and patient-clinician relationships.

In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.

This review suggests a causal relationship between finasteride, used for hair loss, and persistent neuropsychiatric side effects like depression, citing evidence that fulfills key causality criteria and calls for cautious use along with strengthened regulatory oversight.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

The authors concluded that the concept of postfinasteride syndrome remains contentious and may be more plausibly characterized as a psychiatric condition rather than a consistent medical syndrome.

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

This research emphasizes the importance of integrating pre-treatment psychological assessments for individuals considering finasteride, highlighting that these assessments could help identify those prone to nocebo responses, potentially reducing adverse symptom development more related to cognitive vulnerabilities than to the drug itself.

This study found that Annurca apple polyphenolic extracts reprogram hair follicle metabolism in mice, enhancing mitochondrial activity and keratin production while inhibiting some metabolic pathways.

This review explores the inconsistent therapeutic effects and side effects of finasteride for androgenic alopecia, highlighting the need for further research to better predict individual patient responses.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This pharmacovigilance study found an increased association of suicidality and psychological adverse events with finasteride use, especially among younger patients using it for alopecia.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.

This article reviews the safety of finasteride by examining existing literature and does not report new findings, highlighting the ongoing controversies regarding its adverse effects.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

This case report describes a woman who experienced worsened breast implant illness symptoms following a COVID-19 infection and vaccination, which improved after implant removal, even though numerous screenings had been inconclusive prior to explantation.

The congress showed that psychological therapy can help skin condition patients, social media affects acne stigma, education improves atopic dermatitis, and patient satisfaction in dermatology is high, especially with good doctor engagement.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This review discusses the complex interplay between the nervous system and skin conditions, highlighting various treatment strategies, but reports no new research findings.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This review discusses androgenetic alopecia management with 5α-reductase inhibitors, emphasizing that while dutasteride shows superior efficacy, finasteride is suggested as preferable due to predictable adverse effects and preservation of physiological roles.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.